Stock Research for GWPH

GWPH

Featured Broker: Ally Invest

Get the due diligence for another stock.

 

GWPH Stock Chart & Research Data

The GWPH chart settings shown below allow you to select time intervals of 1 min, 30 mins, an hour or by day - week - month. There is also the ability to change the GWPH chart style to candles, hollow candles, bars, lines or add various indicators. You can even add a symbol and compare history.


 


GWPH Due diligence Resources & Stock Charts

The GWPH stock resources shown below were gathered to cut back on time by allowing you to visit multiple sites at once. For your convenience each link clicked will open in a window. In addition to the individual links there is a button at the bottom that will allow you to open all the links at the same time. Note opening all links at once may not work with all browsers. Some browsers block multiple windows, to resolve this please allow that site to use pop-ups.

The Four Most Popular Resources

CNN View GWPH Detailed Price Forecast - CNN Money CNN View GWPH Detailed Summary - Google Finance
Yahoo View GWPH Detailed Summary - Yahoo! Finance Zacks View GWPH Stock Research & Analysis - Zacks.com

Stock Analysis

TradeIdeas View GWPH Trends & Analysis - Trade-Ideas Barrons View GWPH Major Holders - Barrons
NASDAQ View GWPH Call Transcripts - NASDAQ Seeking View GWPH Breaking News & Analysis - Seeking Alpha
Spotlight View GWPH Annual Report - CompanySpotlight.com OTC Report View GWPH OTC Short Report - OTCShortReport.com
TradeKing View GWPH Fundamentals - TradeKing Charts View GWPH SEC Filings - Bar Chart
WSJ View Historical Prices for GWPH - The WSJ Morningstar View Performance/Total Return for GWPH - Morningstar
MarketWatch View the Analyst Estimates for GWPH - MarketWatch CNBC View the Earnings History for GWPH - CNBC
StockMarketWatch View the GWPH Earnings - StockMarketWatch MacroAxis View GWPH Buy or Sell Recommendations - MacroAxis
Bullish View the GWPH Bullish Patterns - American Bulls Short Pains View GWPH Short Pain Metrics - ShortPainBot.com

Social Media Mentions

StockTwits View GWPH Stock Mentions - StockTwits PennyStocks View GWPH Stock Mentions - PennyStockTweets
Twitter View GWPH Stock Mentions - Twitter Invest Hub View GWPH Investment Forum News - Investor Hub
Yahoo View GWPH Stock Mentions - Yahoo! Message Board Seeking Alpha View GWPH Stock Mentions - Seeking Alpha


Financial & Transaction Holdings

SECform4 View Insider Transactions for GWPH - SECform4.com Insider Cow View Insider Transactions for GWPH - Insider Cow
CNBC View GWPH Major Holdings Summary - CNBC OTC Markets View Insider Disclosure for GWPH - OTC Markets
Yahoo View Insider Transactions for GWPH - Yahoo! Finance NASDAQ View Institutional Holdings for GWPH - NASDAQ


Stock Charts

FinViz View GWPH Stock Insight & Charts - FinViz.com StockCharts View GWPH Investment Charts - StockCharts.com
BarChart View GWPH Stock Overview & Charts - BarChart Trading View View GWPH User Generated Charts - Trading View




Latest Financial News for GWPH


Stifel Bullish On GW Pharma, Sees $1.5 Billion In Epidiolex Sales By 2023
Posted on Wednesday August 15, 2018

After a huge year in 2017, GW Pharmaceuticals PLC-ADR (NASDAQ: GWPH) stock has traded mostly sideways so far in 2018. According to Matteis, Epidiolex is such a potential money maker that GW’s story will come down to execution and access. Matteis expects a strong launch for Epidiolex, he predicted an 80 percent chance of success for the drug in Tuberous Sclerosis complex and he said extension of GW's intellectual property over time could all drive upside in the stock.


GW Pharma Updates on Fiscal Q3 Results & Epidiolex Progress
Posted on Monday August 13, 2018

GW Pharmaceuticals (NASDAQ: GWPH), a British biopharma, recently reported its third quarter earnings and progress on its cannabis-based drug for people suffering from epilepsy. The biopharma company reported an EPS of -$1.26 in fiscal Q3 compared with the Thomson Reuters’ estimate of -$2.40, while its top line touched $3.46 million in the quarter compared with Reuters’ estimates of $2 million. Apart from the financials, the highlight of the call was the update on its flagship cannabis-based epilepsy drug Epidiolex, which received U.S. FDA approval in June and will most likely hit the markets this fall.


This U.S. Territory Is on the Verge of Legalizing Marijuana in a Unique Way
Posted on Sunday August 12, 2018

No U.S. state or territory has done this before.


This Shocking Percentage of Americans Believe Marijuana Has at Least 1 Benefit
Posted on Saturday August 11, 2018

A new survey provides depth on the public's perception of cannabis.


Stock Market & Investing Books

Enter a stock symbol to view the stock details.